QL Biotek Presents Dengue, Malaria and G6PD Rapid Tests at Hospitalar 2025 in São Paulo

· By Lisa Zhang, Export Sales Manager · QL Biotek Export Team

Latin America remains one of the most demanding markets for point-of-care infectious disease testing. Mosquito-borne infections drive high patient volumes, while genetic conditions such as glucose-6-phosphate dehydrogenase (G6PD) deficiency complicate treatment protocols for antimalarial drugs. QL Biotek will address both needs directly at Hospitalar 2025, Latin America's largest healthcare trade fair, held at São Paulo Expo in Brazil from May 20 to 23, 2025.

The company will present three rapid diagnostic tests at Booth G420, with live demonstrations available throughout the event and meetings open to distributors, importers and institutional buyers.

Three Rapid Tests Built for Field and Clinic Use

All three assays on display are lateral-flow rapid tests designed for decentralized settings where laboratory infrastructure is limited or turnaround time is critical. They are manufactured under QL Biotek's ISO 13485-certified quality system and carry CE marking.

Dengue Rapid Test

The dengue assay returns results in 15 minutes with high sensitivity and specificity. Its key clinical value lies in the ability to distinguish between primary and secondary dengue infections, a distinction that supports treatment and triage decisions, particularly during outbreak response. The format suits high-throughput screening in clinics, fever referral centers and temporary field laboratories.

Malaria Rapid Test

The malaria test detects parasite antigens in 10 minutes, including at low parasitemia levels. Early and reliable detection matters most in remote regions where patients may travel hours to reach a microscopy-capable facility. For distributors serving endemic zones, the short runtime and minimal equipment requirement simplify deployment in community health posts and mobile screening programs.

G6PD Rapid Test

The G6PD test identifies glucose-6-phosphate dehydrogenase deficiency in 15 minutes. This matters for a specific and growing use case: safe radical cure of malaria. Patients prescribed primaquine or other oxidant drugs risk hemolytic complications if they carry a G6PD deficiency, and pre-treatment screening allows clinicians to adjust dosing or select alternatives. As malaria elimination programs expand the use of 8-aminoquinoline drugs across diverse populations, G6PD status testing becomes a practical prerequisite rather than an optional step.

Why the Combination Matters for Latin America

Brazil and neighbouring countries face a double burden. Dengue incidence continues to stress primary care systems, malaria persists in remote and border regions, and G6PD deficiency prevalence in some populations makes safe antimalarial prescribing a real concern. Offering all three tests in a single rapid-test platform gives buyers a coherent portfolio rather than isolated SKUs.

QL Biotek's solutions are used in more than 50 countries, and the Hospitalar 2025 exhibition is part of the company's direct engagement with the Latin American distribution channel.

What Visitors Can Expect at Booth G420

  • Live demonstrations of the dengue, malaria and G6PD rapid tests, including workflow and reading time.
  • Distribution and partnership discussions for importers, wholesalers and regional agents.
  • Portfolio review covering QL Biotek's broader range of certified rapid tests for infectious diseases and genetic conditions.

According to Nora, Global Sales Director at QL Biotek, the exhibition is a direct response to urgent diagnostic needs in the region: "Our dengue, malaria and G6PD tests exemplify our commitment to innovation that saves lives and strengthens healthcare systems."

Event Details

EventHospitalar 2025
DatesMay 20–23, 2025
LocationSão Paulo Expo, Brazil
BoothG420

To schedule a meeting in advance or request product documentation, contact Nora, Sales Manager, at [email protected] or +86-13136169757. Visit www.qinglibio.com for the full product catalogue.

FAQ

Which rapid tests will QL Biotek display at Hospitalar 2025?

Three tests will be demonstrated at Booth G420: the Dengue Rapid Test (15-minute result, distinguishes primary from secondary infection), the Malaria Rapid Test (10-minute result, detects low parasitemia), and the G6PD Rapid Test (15-minute result, screens for G6PD deficiency before oxidant drug therapy). All are CE-marked and produced under an ISO 13485-certified quality system.

Why is G6PD testing included alongside malaria diagnostics?

Radical cure of malaria often relies on primaquine and other oxidant drugs that can trigger hemolysis in G6PD-deficient patients. A 15-minute G6PD rapid test allows prescribers to identify at-risk patients before treatment begins, supporting safer and more personalized antimalarial therapy across genetically diverse populations.

How can distributors arrange a meeting with QL Biotek at the exhibition?

Interested partners can contact Nora, Sales Manager, by email at [email protected] or by phone at +86-13136169757 to book a slot at Booth G420 during May 20–23, 2025 at São Paulo Expo. Product information is also available at www.qinglibio.com.

Talk to a real person. Questions about this topic, IFUs, samples or pricing? Contact Lisa Zhang (Export Sales Manager) — official quotation within 24 hours.

WhatsApp +86 153 0654 9980 Email Enquiry